vs
Side-by-side financial comparison of Atlantic Union Bankshares Corp (AUB) and Bio-Techne (TECH). Click either name above to swap in a different company.
Atlantic Union Bankshares Corp is the larger business by last-quarter revenue ($367.2M vs $295.9M, roughly 1.2× Bio-Techne). Atlantic Union Bankshares Corp runs the higher net margin — 33.3% vs 12.8%, a 20.4% gap on every dollar of revenue. Over the past eight quarters, Atlantic Union Bankshares Corp's revenue compounded faster (32.7% CAGR vs 4.2%).
Atlantic Union Bankshares Corporation is a bank holding company based in Richmond, Virginia and is the parent company of Atlantic Union Bank, a regional bank. It operates 129 branches in Virginia, Maryland, and North Carolina and is the largest bank headquartered in Virginia. It is on the list of largest banks in the United States.
Bio-Techne Corporation is an American life sciences company that develops, manufactures and sells life science reagents, instruments and services for the research, diagnostic, and bioprocessing markets.
AUB vs TECH — Head-to-Head
Income Statement — Q1 FY2026 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $367.2M | $295.9M |
| Net Profit | $122.2M | $38.0M |
| Gross Margin | — | 64.6% |
| Operating Margin | — | 18.4% |
| Net Margin | 33.3% | 12.8% |
| Revenue YoY | — | -6.4% |
| Net Profit YoY | 145.2% | 68.3% |
| EPS (diluted) | $0.84 | $0.24 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $367.2M | — | ||
| Q4 25 | $387.2M | $295.9M | ||
| Q3 25 | $371.0M | — | ||
| Q2 25 | $402.9M | $317.0M | ||
| Q1 25 | $213.3M | $316.2M | ||
| Q4 24 | $218.5M | $297.0M | ||
| Q3 24 | $217.2M | $289.5M | ||
| Q2 24 | $208.3M | $306.1M |
| Q1 26 | $122.2M | — | ||
| Q4 25 | $112.0M | $38.0M | ||
| Q3 25 | $92.1M | — | ||
| Q2 25 | $19.8M | $-17.7M | ||
| Q1 25 | $49.8M | $22.6M | ||
| Q4 24 | $57.8M | $34.9M | ||
| Q3 24 | $76.4M | $33.6M | ||
| Q2 24 | $25.2M | $40.6M |
| Q1 26 | — | — | ||
| Q4 25 | — | 64.6% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 62.7% | ||
| Q1 25 | — | 67.9% | ||
| Q4 24 | — | 65.3% | ||
| Q3 24 | — | 63.2% | ||
| Q2 24 | — | 66.4% |
| Q1 26 | — | — | ||
| Q4 25 | 36.6% | 18.4% | ||
| Q3 25 | 31.3% | — | ||
| Q2 25 | 4.3% | -7.5% | ||
| Q1 25 | 28.8% | 12.2% | ||
| Q4 24 | 32.6% | 16.0% | ||
| Q3 24 | 42.4% | 13.8% | ||
| Q2 24 | 17.6% | 15.0% |
| Q1 26 | 33.3% | — | ||
| Q4 25 | 28.9% | 12.8% | ||
| Q3 25 | 24.8% | — | ||
| Q2 25 | 4.9% | -5.6% | ||
| Q1 25 | 23.4% | 7.1% | ||
| Q4 24 | 26.4% | 11.7% | ||
| Q3 24 | 35.2% | 11.6% | ||
| Q2 24 | 12.1% | 13.3% |
| Q1 26 | $0.84 | — | ||
| Q4 25 | $0.76 | $0.24 | ||
| Q3 25 | $0.63 | — | ||
| Q2 25 | $0.12 | $-0.11 | ||
| Q1 25 | $0.52 | $0.14 | ||
| Q4 24 | $0.55 | $0.22 | ||
| Q3 24 | $0.82 | $0.21 | ||
| Q2 24 | $0.25 | $0.26 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $172.9M |
| Total DebtLower is stronger | $775.0M | $260.0M |
| Stockholders' EquityBook value | $5.1B | $2.0B |
| Total Assets | $37.3B | $2.5B |
| Debt / EquityLower = less leverage | 0.15× | 0.13× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $966.5M | $172.9M | ||
| Q3 25 | $794.7M | — | ||
| Q2 25 | $1.6B | $162.2M | ||
| Q1 25 | $434.1M | $140.7M | ||
| Q4 24 | $354.1M | $177.5M | ||
| Q3 24 | $528.1M | $187.5M | ||
| Q2 24 | $446.0M | $152.9M |
| Q1 26 | $775.0M | — | ||
| Q4 25 | $771.9M | $260.0M | ||
| Q3 25 | $768.7M | — | ||
| Q2 25 | $765.4M | $346.0M | ||
| Q1 25 | $418.7M | $330.0M | ||
| Q4 24 | $418.3M | $300.0M | ||
| Q3 24 | $417.9M | $300.0M | ||
| Q2 24 | $416.6M | $319.0M |
| Q1 26 | $5.1B | — | ||
| Q4 25 | $5.0B | $2.0B | ||
| Q3 25 | $4.9B | — | ||
| Q2 25 | $4.8B | $1.9B | ||
| Q1 25 | $3.2B | $2.0B | ||
| Q4 24 | $3.1B | $2.1B | ||
| Q3 24 | $3.2B | $2.1B | ||
| Q2 24 | $3.0B | $2.1B |
| Q1 26 | $37.3B | — | ||
| Q4 25 | $37.6B | $2.5B | ||
| Q3 25 | $37.1B | — | ||
| Q2 25 | $37.3B | $2.6B | ||
| Q1 25 | $24.6B | $2.6B | ||
| Q4 24 | $24.6B | $2.7B | ||
| Q3 24 | $24.8B | $2.7B | ||
| Q2 24 | $24.8B | $2.7B |
| Q1 26 | 0.15× | — | ||
| Q4 25 | 0.15× | 0.13× | ||
| Q3 25 | 0.16× | — | ||
| Q2 25 | 0.16× | 0.18× | ||
| Q1 25 | 0.13× | 0.16× | ||
| Q4 24 | 0.13× | 0.14× | ||
| Q3 24 | 0.13× | 0.14× | ||
| Q2 24 | 0.14× | 0.15× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AUB
| Net Interest Income | $312.4M | 85% |
| Noninterest Income | $54.8M | 15% |
TECH
| Diagnostics And Spatial Biology | $81.2M | 27% |
| EMEA Excluding UK | $75.4M | 25% |
| Other | $42.4M | 14% |
| Instruments | $29.6M | 10% |
| APAC Excluding Greater China | $22.7M | 8% |
| Services | $22.3M | 8% |
| GB | $13.7M | 5% |
| Royalty | $8.5M | 3% |
